Horizon Pharma plc (HZNP) : Traders are bullish on Horizon Pharma plc (HZNP) as it has outperformed the S&P 500 by a wide margin of 10.62% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.69%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.19% in the last 1 week, and is up 15.46% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 10.86% and the 50-Day Moving Average is 15.27%.
Horizon Pharma plc (NASDAQ:HZNP): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.83 and $18.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $19.25. The buying momentum continued till the end and the stock did not give up its gains. It closed at $19.12, notching a gain of 2.30% for the day. The total traded volume was 2,775,735 . The stock had closed at $18.69 on the previous day.
The company Insiders own 2.1% of Horizon Pharma plc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -11.64% . Institutional Investors own 86.87% of Horizon Pharma plc shares. During last six month period, the net percent change held by insiders has seen a change of -7.9%. In a related news, The Securities and Exchange Commission has divulged that Nohria Virinder, director of Horizon Pharma Plc, had unloaded 25,000 shares at an average price of $17.69 in a transaction dated on June 15, 2016. The total value of the transaction was worth $442,250.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.